Education
About Us
Working with TipRanks
Follow Us
Movano, Inc. (MOVE)
:MOVE
Top Page
Movano
(NASDAQ:MOVE)
27Underperform
Movano (MOVE) vs. S&P 500 (SPY)
Market Cap
$6.05M
Dividend YieldN/A
Average Volume (3M)35.33K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue GrowthN/A
EPS Growth56.73%
CountryUS
Employees30
SectorHealthcare
Sector Strength71
IndustryMedical - Devices
Share Statistics
EPS (TTM)-4.20
Shares Outstanding7,036,953
10 Day Avg. Volume57,703
30 Day Avg. Volume35,332
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)15.08
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Movano Business Overview & Revenue Model
Company DescriptionMovano Inc. (MOVE) is a health-focused technology company that operates in the wearable healthcare device sector. The company is dedicated to developing innovative solutions that empower individuals to monitor and manage their health. Movano's core product is a wearable device designed to provide continuous, real-time health data, helping users track vital signs and other health metrics seamlessly. The company's mission is to enhance health awareness and improve the quality of life through accessible and actionable health insights.
How the Company Makes MoneyMovano makes money primarily through the sale of its wearable healthcare devices. The company's revenue model revolves around direct sales to consumers, partnerships with healthcare providers, and potentially through subscription-based services that offer enhanced features or data analytics. Movano may also explore partnerships with insurance companies or corporate wellness programs, leveraging its technology to offer value-added services. Additionally, Movano could generate revenue from licensing its technology to other companies in the healthcare and technology sectors. These revenue streams are supported by ongoing research and development, aimed at expanding the capabilities and market reach of its products.
Movano Financial Statement Overview
Summary
Movano faces significant challenges in profitability and cash flow, with initial revenue generation but continued high costs and operational losses. The balance sheet remains relatively stable with moderate leverage but is offset by weak cash flow performance, necessitating careful financial management to support future growth prospects.Income Statement
Movano has struggled to generate revenue, with the first recorded revenue in TTM (Trailing-Twelve-Months) at $1.13 million. The gross profit margin is negative due to high costs exceeding revenue. Net profit margin is also negative, reflecting ongoing losses. Despite a slight revenue emergence, the company continues to face significant profitability challenges with negative EBIT and EBITDA margins.30
Negative
Balance Sheet
The balance sheet shows moderate strength with positive stockholders' equity. However, the debt-to-equity ratio is low, indicating minimal leverage. The equity ratio stands at 68.07%, suggesting a solid equity base compared to assets. While liabilities are managed, the company has experienced asset fluctuations and historical equity deficits.45
Neutral
Cash Flow
The cash flow statement highlights negative free cash flow, indicating more cash outflow than inflow from operations and investments. Operating cash flow to net income ratio is negative, reflecting operational cash challenges. However, financing activities have provided necessary liquidity, stabilizing cash positions.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.13M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
| -1.35M | -158.00K | -134.00K | -74.00K | -13.00K | -11.00K | EBIT |
| -25.55M | -29.69M | -30.46M | -19.80M | -11.11M | -8.51M | EBITDA |
| -25.41M | -29.13M | -30.20M | -20.82M | -11.07M | -8.50M | Net Income Common Stockholders |
| -25.07M | -29.28M | -30.20M | -22.58M | -14.04M | -8.44M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 4.29M | 6.12M | 10.76M | 33.60M | 5.71M | 4.29M | Total Assets |
| 4.89M | 9.42M | 13.24M | 36.27M | 7.08M | 4.89M | Total Debt |
| 0.00 | 217.00K | 426.00K | 0.00 | 11.69M | 0.00 | Net Debt |
| -4.29M | -5.90M | -10.33M | -17.68M | 5.98M | -4.29M | Total Liabilities |
| 890.00K | 5.97M | 5.33M | 3.54M | 15.14M | 890.00K | Stockholders Equity |
| 4.00M | 3.45M | 7.92M | 32.73M | -8.06M | 4.00M |
| Cash Flow | Free Cash Flow | ||||
| -23.24M | -26.24M | -25.01M | -16.75M | -10.67M | -8.24M | Operating Cash Flow |
| -23.23M | -26.18M | -24.90M | -16.18M | -10.67M | -8.23M | Investing Cash Flow |
| -16.00K | -64.00K | 15.72M | -16.70M | 0.00 | -13.00K | Financing Cash Flow |
| 26.85M | 21.60M | 2.26M | 44.85M | 12.09M | 9.36M |
Movano Technical Analysis
Negative
0.81
Price Trends
3.26
Negative
4.28
Negative
4.63
Negative
Market Momentum
-0.68
Negative
13.70
Positive
10.89
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MOVE, the sentiment is Negative. The current price of 0.81 is below the 20-day moving average (MA) of 1.61, below the 50-day MA of 3.26, and below the 200-day MA of 4.63, indicating a bearish trend. The MACD of -0.68 indicates Negative momentum. The RSI at 13.70 is Positive, neither overbought nor oversold. The STOCH value of 10.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MOVE.
Movano Risk Analysis
Movano disclosed 38 risk factors in its most recent earnings report. Movano reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Movano Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $36.51B | 25.99 | 19.00% | 1.58% | 20.44% | 9.05% | |
75 Outperform | $154.01B | 14.88 | 41.96% | 2.44% | 12.13% | 36.17% | |
71 Outperform | $6.29B | 52.94 | 30.71% | ― | 69.33% | ― | |
66 Neutral | $80.28B | 18.10 | 31.93% | 2.83% | -7.11% | -12.12% | |
48 Neutral | $6.46B | 1.17 | -48.25% | 2.67% | 19.50% | 0.61% | |
44 Neutral | $108.95M | 124.10 | 111.75% | ― | 5.41% | ― | |
27 Underperform | $6.05M | ― | -439.23% | ― | ― | 56.73% |
* Healthcare Sector Average
Performance Comparison
MOVE
Movano
0.86
-6.61
-88.49%
GRMN
Garmin
192.10
52.69
37.79%
NKE
Nike
55.41
-35.98
-39.37%
QCOM
Qualcomm
139.19
-27.31
-16.40%
INSG
Inseego
7.43
5.11
220.26%
HIMS
Hims & Hers Health
28.31
15.09
114.15%
Movano Earnings Call Summary
Earnings Call Date: Mar 19, 2025 | % Change Since: -66.94% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call highlighted several achievements, including successful sales of the Evie Rings, progress towards FDA clearance, and positive customer feedback. However, challenges such as stock price issues and financial concerns were also discussed. Overall, the sentiment leans slightly positive due to the company's forward momentum and strategic planning.Highlights
Successful Sale of Evie Rings
Movano Health reported ongoing successful sales and fulfillment of Evie Rings following a back in-stock announcement on September 17.
Anticipated FDA Clearance for EvieMed Ring
Movano Health is in the final stages of the FDA 510(k) review process for the EvieMed ring, with positive progress towards clearance.
B2B Commercial Opportunities
The company is preparing to deliver its first B2B commercial opportunities with healthcare partners shortly after gaining FDA clearance.
Positive Customer Feedback
The company received a consistent 90%-plus customer service approval score, indicating a positive response to improvements in app features, operations, and customer service.
Efficient Customer Acquisition
Movano Health achieved an extremely efficient customer acquisition cost through organic marketing efforts.
Improved Financial Position
The company reported an operating loss of $7.4 million in Q3 2024, an improvement from $9.1 million in the previous year, with a cash reserve of $11.3 million.
Lowlights
Stock Price and Reverse Split Issues
Movano implemented a 1-for-15 reverse stock split to regain compliance with NASDAQ listing requirements, and is investigating potential stock manipulation during the process.
Continued Cash Burn
The company experienced a cash burn of approximately $5.6 million in the quarter, indicating ongoing financial challenges.
Pending FDA Clearance Delays
Despite positive progress, the company is still awaiting final FDA clearance for the EvieMed ring, with no specific timeline for resolution.
Company Guidance
During the Movano Health Q3 2024 earnings call, the company provided guidance on several key metrics and strategic initiatives. Movano Health is optimistic about both its direct-to-consumer (D2C) and business-to-business (B2B) opportunities, emphasizing the EvieMed ring's anticipated FDA 510(k) clearance. The company has successfully shipped 339 Evie rings since resuming sales in September, achieving a 90%+ customer service approval score. It plans to capitalize on the upcoming Black Friday/Cyber Monday sales period with an entirely organic marketing strategy, resulting in efficient customer acquisition costs. Financially, Movano reported a Q3 operating loss of $7.4 million, down from $9.1 million in the previous year, with a cash position of $11.3 million as of September 30, 2024. The company continues to manage its cash burn carefully, which was approximately $5.6 million for the quarter. Additionally, Movano is exploring commercial opportunities with major pharmaceutical and healthcare partners, preparing for a pilot program in Q1 2025, and advancing its blood pressure and glucose monitoring technologies.Movano Corporate Events
Executive/Board Changes
Movano Appoints Shaheen Wirk to Board of Directors
Neutral
Jan 2, 2025
Movano Inc. has appointed Shaheen Wirk as a Class III director, who will also serve on the Audit Committee. This appointment is part of Movano’s ongoing corporate governance strategies, with Wirk receiving stock options as compensation, indicating a focus on aligning director interests with shareholder value.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.